Objective: Patients with cancer face difficult decisions regarding treatment and the possibility of trading quality of life (QoL) for length of life (LoL). Little information is available regarding patients' preferences and attitudes toward their cancer treatment and the personal costs they are prepared to exchange to extend their life. The aim of this review is to determine the complex trade-offs and underpinning factors that make patients with cancer choose quality over quantity of life.
harms. 1 The primary focus of cancer treatment has always been to increase overall and disease free survival; however, quality of life (QoL) has been increasingly recognized as an important end point. 2 Although there is an instinctive understanding of the term "quality of life," there are multiple definitions, which gives testimony to the fact that it is a complex concept with many diverse facets and components. The standard dimensions used in QoL questionnaires measure the presence or absence of specific symptoms or overall general health. They do not measure patients' beliefs or attitudes toward treatment and intervention outcomes. 3 Decision making in a cancer setting can be a difficult process due to its multifaceted nature. The patients' outlook and beliefs are paramount, but this is heavily influenced by their own experiences and those of friends and family. 4 In addition, current QoL and physical status can affect subsequent decisions.
Most cancer trials primarily focus on the standard oncology end points relating to survival, but it is possible to derive composite measures, which assess the impact of QoL on the final outcome of different therapies. These are called quality adjusted survival metrics or health utility metrics, and a wide range of them have been developed over the past 30 years. Utility measures allow patients a chance to value a different perspective on treatment and outcomes. Two methods of utility measurement that may be used to calculate quality adjusted life years (QALY) or quality adjusted survival are standard gamble and time trade-off (TTO). 5 In standard gamble, patients are asked to choose between staying in a state of ill health for a specified time period or choosing a treatment that may either cause their death or restore perfect health. In the case of TTO, the individual expresses a preference between two choices, usually between LoL or a better health status. 4 These methods have been increasingly adapted in cost-utility analyses of pharmaceuticals and various health-care interventions. In reality, scenarios are often more complex with disease and treatment effects impacting variably on QoL over a prolonged time course. There may be a significant drop in QoL after an intervention but an overall better long-term QoL and increased life expectancy. QoL measurement should not just focus on a single time point when assessing an intervention.
In cancer treatment, patients are often required to make trade-offs between QoL and length of life (LoL). 6 Tumor-specific therapy can potentially prolong life; however, this may reduce QoL significantly.
Some patients are willing to endure toxicities associated with treatment in order to increase their LoL, while others value QoL more and are reluctant to spend their remaining years in a compromised state. 7 This involves weighing the risks and benefits of treatment and managing the patients' concerns and expectations. There may be personal reasons associated with their health, the effect on their family and friends, and the consequences of the treatment itself. A tradeoff for potential gain in life expectancy may involve short-term debility from treatment (postsurgical pain, chemotherapy-induced nausea and alopecia, and etc) or permanent side effects (stoma, disfigurement, physical dependency, and etc). Moreover, the compromise is not always related to health but instead may be about financial burdens and increased dependency on friends and family.
To understand cancer treatment choices concerning trade-off, various questionnaires and methodologies have been devised to understand patient preferences and priorities toward cancer treatment.
Quality-adjusted time without symptoms or toxicity (Q-Twist) allows the combination of both quality and quantity of survival time. 8, 9 The principle hypothesis of this method is that patients without disease symptoms or treatment toxicity have a better health-related quality of life (HrQoL) than those who have disease-specific symptoms and toxicity. Q-TWiST was initially used to assess adjuvant therapy for breast cancer and has now been adapted in other cancers. [10] [11] [12] The Quality/Quantity Questionnaire designed by Stiggelbout and colleagues was created to assess patients' preferences toward either QoL or LoL when deciding about cancer treatments. 7 Other methods include discrete choice experiments and various bespoke questionnaires tailored to a specific study. [13] [14] [15] The aim of this review was to determine the factors influencing patient preferences for either QoL or LoL and how these impacts on cancer treatment choices. publications for more details concerning study methods and design, those publications were also acquired.
| Data abstraction
Data extraction was performed by two independent reviewers (A.S.
and C.M.). The information collected included study design, aim of study, location of study, sample size and response rate, age of the sample, type of cancer, any research tools used in the form of questionnaires and the findings of the study relating to QoL versus LoL preferences.
| Quality assessment
The Mixed Methods Appraisal Tool (MMAT) was used to quality assess the articles that were included in the study. For each item the response categories were "yes," "no," or "can't tell" followed by comments. 16 Higher quality is denoted by the number of stars (*) in the tables. Quality assessment was independently scored by two reviewers (A.S. and C.M.). No study was excluded based on quality assessment, as all were of acceptable quality.
| RESULTS
The literature search revealed 4388 articles. A total of 843 abstracts were excluded because of duplication, and 3494 articles were declined as they were either reviews, expert opinions/editorials, or not suitable for the topic under review. A total of 56 articles were reviewed fully, and only 30 deemed suitable for inclusion. The 26 rejected papers
were not suitable as they were either reviews or not relevant ( Figure 1 ). Included studies are summarized in Tables 1 (quantitative), 2 (mixed methods), and 3 (purely qualitative) (Tables 2 and 3 ).
The majority of studies identified in this review were quantitative.
Generic questionnaires (EORTC-QLQ-C30 and FACT-G) and disease specific questionnaires (EORTC-QLQ-H&N) were used to assess
QoL. The studies were mainly conducted to understand the decision-making process in the advanced cancer setting. The studies had wide focus that included understanding the role of the doctor and the attitude the patient has toward their treatment, among other themes. Understanding QoL and LoL trade-offs as part of the decision-making process, usually formed a limited part of many of these studies.
| QoL versus LoL
Meropol and colleagues (2008) suggested that QoL and LoL are both equally important; however, the majority of patients with advanced cancer in this study prioritized QoL over LoL. 41 This was also reflected • Overall 55% felt both were equally important.
*** (Continues) 
Cancer TherapyGeneral (FACT-G)
• Cancer
Communication
Assessment Tool for patients (CCAT-P)
• Questionnaire on Stress in Cancer Patients (QSC-R10)
• by the study of Jenkins and associates. 36 Silvestri and associates noted although there were some patients who would endure treatment and associated toxicities just to live a single day longer, there were also patients who would decline all treatments. These latter patients would rather maintain their QoL and having to withstand the adverse effects of treatment would not be a worthwhile trade-off. 20 The authors postulated that patients may opt for enhanced QoL only if the chance of survival was less than 50% relative to baseline survival (without treatment). 42 Many patients in the study by Brom and colleagues felt that they ought to have some sort of intervention for their cancer and found it difficult to accept the concept of LoL and QoL. Although some patients opted for treatment initially, they expressed the view that if it was affecting their QoL, they would cease treatment. 39 Marta and colleagues noted that the majority of patients in their study wanted to undergo a treatment that would prolong life but not compromise their QoL. 43 In a qualitative study by Gerber and colleagues, patients stated that they were keen to maintain their activities and not be a burden on family, and therefore not undergo chemotherapy if those factors were compromised, indicating the importance of QoL. 38 
| Survival and baseline QoL
Survival seemed to be a key feature in the decision-making process and patients were found to opt for treatment if they felt that their prognosis was likely to improve. 15, 19, 28, 40 Their current health status also affected their choice. Perez and associates found that those who wanted to trade time, scored lower in many of the domains of the baseline HRQoL questionnaires. 3 Patients in better health were found to rate LoL more highly, whereas those who were in poorer health strived to maintain their QoL. 7, 22, 32, 44 Kiebert and associates noted that issues patients felt were important were baseline QoL and the probability of survival. 17 
| Demographic factors
Kiebert and associates assessed factors affecting decision making for cancer treatment and noted that important factors were age, marital status, children, inability to work due to side effects, disease related life expectancy, and baseline QoL. No significant associations were found between the various determinants; however, patients did rate having children and marital status as somewhat important in decision making. 17 Other studies have shown different results, with gender, children, education, religion, and cancer type not influencing treatment choices. 3, 6, 23, 35 Those with strong family links preferred survival.
Unemployed patients prioritized QoL. 6 Wong and colleagues concluded that those who were able to pay for their treatment chose to have treatment to prolong their life. 45 These latter findings are only relevant in self paying health care systems.
Many of the studies carried out have not been age specific; therefore, it has been difficult to make inferences about the influence of • FACT-G • Interview
• 20 patients would undergo palliative intervention to treat cancer or live longer.
• 47% for symptom control/better QoL This review highlights the importance of carrying out baseline QoL assessments prior to treatment and evaluating the impact of life expectancy. The importance of performing age specific studies is also noted as priorities between younger and older patients are different.
The preferences for QoL or LoL by younger patients, may be influenced by their desire to spend time with their partner or children.
Older patients are more likely to suffer from multiple comorbidities and be frailer, and discussions may need to include whether a treatment will be tolerated less well because of these limitations, or result in an increased risk of harm. Considerations should include patient intolerance to certain chemotherapy agents or surgery, as well as an understanding that they may never reach their preoperative baseline physical fitness again after treatment. This "step down" in function tends to be more prominent in the older age group, 47, 48 patients is a recommendation from doctors. 50 In breast cancer, undertreatment is well-documented in older patients. 51 This has led to avoidable disease-specific deaths. 52 Exploring the patients' views regarding treatment at an early stage would help reduce the impact of age-related clinician bias, which is well recognized. 
| Study limitations
This study is the first to use a rigorous and systematic approach to review studies based on patient preferences regarding QoL or LoL in a cancer treatment setting. Despite a comprehensive database search strategy, it is possible that some relevant articles may have been missed and despite the various methodologies, all papers included were of an acceptable design and standard for inclusion. However, the main findings of the review are likely to be robust to missing studies. On the basis of our interpretation and weighting of the evidence, we are confident in the conclusions that have been drawn from findings across several studies rather than be based on isolated studies.
None of the studies in this review has looked at the impact of Many of these studies have mainly focused on advanced cancers of all types. For patients who are facing mortality imminently, the decision to prioritize QoL and LoL is pertinent. In the case of slow growing cancers such as prostate and breast cancers, where conservative management is widely accepted, the choice between QoL and LoL can be more complicated. Patients often die from other causes rather than the cancer itself. 54 As the majority of the articles identified in this search did not involve early stage cancer, it is difficult to know what patients envisage from their treatment and what trade-offs they were willing to make as well as how these factors may change with the course of the natural disease process. This is where patients' age and comorbidities may play a larger role in whether the patient opts for QoL or LoL.
| Clinical implications
This review has several important clinical and research implications. This may go a long way in elucidating what aspects of their life they are willing to trade to maintain their QoL or increase LoL. Older age specific issues and cancer specific decision-making processes also need exploring.
